Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma
作者： C. Haioun , N. Mounier , J.F. Emile , D. Ranta , B. Coiffier
关键词:
摘要: Background: This study compared the induction regimens doxorubicin, cyclophosphamide and etoposide (ACE) with cyclophosphamide, vincristine, bleomycin prednisone (ACVBP) before high-dose therapy (HDT) followed by autologous stem-cell transplantation (ASCT) for patients poor-risk diffuse large B-cell lymphoma (DLBCL). A second randomisation rituximab observation post-ASCT. Materials methods: Four hundred seventy-six <60 years old newly diagnosed CD20+ DLBCL were randomised to ACE or ACVBP. Three thirty responders received HDT ASCT. After ASCT, 269 re-randomised receive either maintenance alone. Randomisation was stratified quality of response The primary end point this event-free survival (EFS). Results: At a median 4 years' follow-up from randomisation, there trend (P = 0.1) towards increased EFS who observation. Conclusion: type (ACVBP ACE) did not significantly affect overall at 51 months' follow-up.
annalsofoncology.org
paperity.org
oxfordjournals.org
oup.com 参考文章(33)
V. Diehl, A. Lister, J.A. Radford, D. Ma, P. Johnson, A. Engert, F. Reyes, C. Haioun, H. Tilly, R. Capdeville, B. Coiffier, N. Ketterer, M. Feuring Buske, Rituximab (Anti-CD20 Monoclonal Antibody) for the Treatment of Patients With Relapsing or Refractory Aggressive Lymphoma: A Multicenter Phase II Study Blood. ,vol. 92, pp. 1927- 1932 ,(1998) , 10.1182/BLOOD.V92.6.1927
C Haioun, E Lepage, C Gisselbrecht, Y Bastion, B Coiffier, P Brice, A Bosly, B Dupriez, C Nouvel, H Tilly, P Lederlin, P Biron, J Brière, P Gaulard, F Reyes, Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte. Journal of Clinical Oncology. ,vol. 15, pp. 1131- 1137 ,(1997) , 10.1200/JCO.1997.15.3.1131
Corinne Haioun, Eric Lepage, Christian Gisselbrecht, Gilles Salles, Bertrand Coiffier, Pauline Brice, André Bosly, Pierre Morel, Christiane Nouvel, Hervé Tilly, Pierre Lederlin, Catherine Sebban, Josette Brière, Philippe Gaulard, Félix Reyes, Survival Benefit of High-Dose Therapy in Poor-Risk Aggressive Non-Hodgkin’s Lymphoma: Final Analysis of the Prospective LNH87–2 Protocol—A Groupe d’Etude des Lymphomes de l’Adulte Study Journal of Clinical Oncology. ,vol. 18, pp. 3025- 3030 ,(2000) , 10.1200/JCO.2000.18.16.3025
Bruce D. Cheson, Sandra J. Horning, Bertr Coiffier, Margaret A. Shipp, Richard I. Fisher, Joseph M. Connors, T. Andrew Lister, Julie Vose, Antonio Grillo-López, Anton Hagenbeek, Fernando Cabanillas, Donald Klippensten, Wolfgang Hiddemann, Ronald Castellino, Nancy L. Harris, James O. Armitage, William Carter, Richard Hoppe, George P. Canellos, Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas Journal of Clinical Oncology. ,vol. 17, pp. 1244- 1244 ,(1999) , 10.1200/JCO.1999.17.4.1244
D Coso, C Sebban, O Boulat, P Biron, J Rey, T Aurran, C Chabannon, L Xerri, B Chetaille, B Esterni, V Ivanov, A M Stoppa, J M Schiano de Collela, J A Gastaut, D Maraninchi, R Bouabdallah, A phase II trial of rituximab as adjuvant to intensive sequential chemotherapy in patients under 60 years with untreated poor-prognosis diffuse large B-cell lymphoma Bone Marrow Transplantation. ,vol. 38, pp. 217- 222 ,(2006) , 10.1038/SJ.BMT.1705414
Michel Meignan, Corinne Haioun, Emmanuel Itti, Alain Rahmouni, Felix Reyes, Value of [18F]Fluorodeoxyglucose–Positron Emission Tomography in Managing Adults with Aggressive Non-Hodgkin's Lymphoma Clinical Lymphoma, Myeloma & Leukemia. ,vol. 6, pp. 306- 313 ,(2006) , 10.3816/CLM.2006.N.005
Raquel Malumbres, Jun Chen, Rob Tibshirani, Nathalie A. Johnson, Laurie H. Sehn, Yaso Natkunam, Javier Briones, Ranjana Advani, Joseph M. Connors, Gerald E. Byrne, Ronald Levy, Randy D. Gascoyne, Izidore S. Lossos, Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Blood. ,vol. 111, pp. 5509- 5514 ,(2007) , 10.1182/BLOOD-2008-02-136374
C Tarella, , M Zanni, M Di Nicola, C Patti, R Calvi, A Pescarollo, V Zoli, A Fornari, D Novero, A Cabras, M Stella, A Comino, D Remotti, M Ponzoni, D Caracciolo, M Ladetto, M Magni, L Devizzi, R Rosato, M Boccadoro, M Bregni, P Corradini, A Gallamini, I Majolino, S Mirto, A M Gianni, Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) Leukemia. ,vol. 21, pp. 1802- 1811 ,(2007) , 10.1038/SJ.LEU.2404781
Douglas A. Stewart, Nizar Bahlis, Karen Valentine, Alex Balogh, Lynn Savoie, Donald G. Morris, Allan Jones, Chris Brown, James A. Russell, Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma. Blood. ,vol. 107, pp. 4623- 4627 ,(2006) , 10.1182/BLOOD-2005-12-4898
Bertrand Coiffier, Eric Lepage, Josette Brière, Raoul Herbrecht, Hervé Tilly, Reda Bouabdallah, Pierre Morel, Eric Van Den Neste, Gilles Salles, Philippe Gaulard, Felix Reyes, Pierre Lederlin, Christian Gisselbrecht, CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma The New England Journal of Medicine. ,vol. 346, pp. 235- 242 ,(2002) , 10.1056/NEJMOA011795